NCT04008368View on ClinicalTrials.gov

Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 24, 2019

Primary Completion Date

January 30, 2030

Study Completion Date

December 1, 2037

Conditions
Myeloid Chimerism
Interventions
DEVICE

CliniMACS CD34 Reagent

Haploidentical recipients will receive CD34-selected cells using Miltenyi CliniMACS CD34+ cell selection kits. The target CD34+ cell dose is at least 10 x 106/kg, and the minimum CD34+ cell dose is 5 x 106/kg. All of the cells collected during the apheresis procedure will be given. The cells will be cryopreserved and stored until the day of transplant.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH